Eagle Pharmaceuticals Inc (NAS:EGRX)
$ 3.54 -0.27 (-7.09%) Market Cap: 45.87 Mil Enterprise Value: 105.50 Mil PE Ratio: 3.89 PB Ratio: 0.18 GF Score: 62/100

Q4 2020 Eagle Pharmaceuticals Inc Earnings Call Transcript

Mar 02, 2021 / 01:30PM GMT
Release Date Price: $40.4 (-10.97%)
Operator

Good morning, everyone. My name is Leo, and I'll be your conference operator. At this time, I'd like to welcome everyone to Eagle Pharmaceuticals' Fourth Quarter and Full Year 2020 Financial Results and Pipeline Review Call. (Operator Instructions) As a reminder, this call -- conference call is being recorded today, March 2, 2021.

It is now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. Please go ahead.

Lisa Wilson

Thank you, operator. Welcome to Eagle Pharmaceuticals' Fourth Quarter 2020 Earnings and Pipeline Review Call. This is Lisa Wilson, Investor Relations for Eagle Pharmaceuticals.

With me on today's call are Eagle's Chief Executive Officer, Scott Tarriff; Chief Financial Officer, Brian Cahill; President and Chief Operating Officer, David Pernock; and Chief Medical Officer, Dr. Judith Ng-Cashin.

This morning, the company issued a press release detailing financial results for the 3 months ended December 31, 2020. This press release and a webcast of this call can be accessed

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot